首页 > 最新文献

Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru最新文献

英文 中文
Cáncer colorrectal post-colonoscopia: Evaluación de una cohorte en sus características clínicas, colonoscópicas, sobrevida y sus causas según la Organización Mundial de Endoscopia 结肠镜后结直肠癌:根据世界内窥镜组织对其临床、结肠镜特征、生存和病因的队列评估
Q4 Medicine Pub Date : 2023-09-30 DOI: 10.47892/rgp.2023.433.1517
Rodrigo Castaño-Llano, Diego Caycedo-Medina, Juan Darío Puerta, Juan Ricardo Jaramillo, Luis Palacios, Mauricio Rodríguez, Sandra Molina, Camilo Vásquez, Santiago Salazar, Juan Esteban Puerta, Isabella Cadavid
Cáncer colorrectal post-colonoscopia (CCRP) es el tumor que aparece posterior a una colonoscopia normal antes de cumplirse el tiempo establecido para seguimiento endoscópico. Origen multifactorial, refleja la calidad de la colonoscopia y las diferentes biologías tumorales entre los cánceres colorrectales detectados (CCRD) y el CCRP. Nuestro objetivo es describir las características del CCRP en nuestro medio, identificar factores de riesgo, discriminar sus causas según la Organización Mundial de Endoscopia (OME) y determinar el efecto en la sobrevida del paciente. El estudio se realizó en pacientes con cáncer-colorrectal (CCR) atendidos en consulta de gastro-oncología de dos instituciones en Medellín-Colombia, entre enero de 2012 y diciembre de 2021 que se habían sometido a una colonoscopia en los 6 a 36 meses anteriores a la colonoscopia en la que se diagnosticó el CCR. 919 pacientes durante 10 años por CCR, 68 casos de CCRP (6,9%), se encontró que se presenta con más frecuencia en pacientes mayores (74 vs. 66 años; p=0,03), con antecedentes de pólipos adenomatosos (36,8% vs. 20,1%; p=0,01) y en colon derecho (57,4% vs. 40,6%; p=0,006), con una tendencia en pacientes con diverticulosis (41,2% vs. 31,3%; p=0,05) y diabetes (25% vs. 14%; p=0,06); menor sobrevida a 5 y 10 años (58%-55,2% vs. 67%-63%; p<0,001). Según la OME, los CCRP se presentaron en 61,3% por lesiones omitidas en colonoscopias inadecuadas, 29% colonoscopias adecuadas y 9,7% resecciones incompletas de adenomas. En conclusión, la tasa de CCRP fue de 6,9%, con mayor propensión en pacientes de mayores, antecedente de resección de pólipos, y en colon derecho. Acorde a la OME, las lesiones omitidas más frecuentemente se relacionaron con colonoscopias inadecuadas. Los pacientes con CCRP tienen menor sobrevida.
结肠镜后结直肠癌(crp)是在正常结肠镜检查后出现的肿瘤,在内窥镜监测的时间完成之前。多因素起源,反映了结肠镜检查的质量和检测到的结直肠癌(crd)和crp的不同肿瘤生物学。我们的目标是描述我们环境中CCRP的特征,识别危险因素,根据世界内窥镜组织(OME)区分其原因,并确定对患者生存的影响。进行cáncer-colorrectal (CCR)接受治疗患者在Medellín-Colombia gastro-oncología查询两个机构,2012年1月至12月续约后,使一个colonoscopia在6至36个月前colonoscopia确诊CCR。919例10年crc患者,68例crp(6.9%),发现老年患者(74岁vs. 66岁;有腺瘤性息肉病史(36.8% vs. 20.1%;p= 0.01)和右结肠(57.4% vs. 40.6%;p= 0.006),憩室病患者有倾向(41.2% vs. 31.3%;p= 0.05)和糖尿病(25% vs. 14%;p = 0.06);5年和10年生存率较低(58%- 55.2% vs. 67%-63%;p< 0.001)。根据OME, 61.3%的crp是由于不充分的结肠镜检查遗漏的病变,29%是适当的结肠镜检查,9.7%是腺瘤不完全切除。在一项随机对照试验中,年龄较大的患者、既往息肉切除的患者和右结肠患者的pcrc患病率为6.9%。根据OME,遗漏的病变最常与不充分的结肠镜检查有关。CCRP患者的生存率较低。
{"title":"Cáncer colorrectal post-colonoscopia: Evaluación de una cohorte en sus características clínicas, colonoscópicas, sobrevida y sus causas según la Organización Mundial de Endoscopia","authors":"Rodrigo Castaño-Llano, Diego Caycedo-Medina, Juan Darío Puerta, Juan Ricardo Jaramillo, Luis Palacios, Mauricio Rodríguez, Sandra Molina, Camilo Vásquez, Santiago Salazar, Juan Esteban Puerta, Isabella Cadavid","doi":"10.47892/rgp.2023.433.1517","DOIUrl":"https://doi.org/10.47892/rgp.2023.433.1517","url":null,"abstract":"Cáncer colorrectal post-colonoscopia (CCRP) es el tumor que aparece posterior a una colonoscopia normal antes de cumplirse el tiempo establecido para seguimiento endoscópico. Origen multifactorial, refleja la calidad de la colonoscopia y las diferentes biologías tumorales entre los cánceres colorrectales detectados (CCRD) y el CCRP. Nuestro objetivo es describir las características del CCRP en nuestro medio, identificar factores de riesgo, discriminar sus causas según la Organización Mundial de Endoscopia (OME) y determinar el efecto en la sobrevida del paciente. El estudio se realizó en pacientes con cáncer-colorrectal (CCR) atendidos en consulta de gastro-oncología de dos instituciones en Medellín-Colombia, entre enero de 2012 y diciembre de 2021 que se habían sometido a una colonoscopia en los 6 a 36 meses anteriores a la colonoscopia en la que se diagnosticó el CCR. 919 pacientes durante 10 años por CCR, 68 casos de CCRP (6,9%), se encontró que se presenta con más frecuencia en pacientes mayores (74 vs. 66 años; p=0,03), con antecedentes de pólipos adenomatosos (36,8% vs. 20,1%; p=0,01) y en colon derecho (57,4% vs. 40,6%; p=0,006), con una tendencia en pacientes con diverticulosis (41,2% vs. 31,3%; p=0,05) y diabetes (25% vs. 14%; p=0,06); menor sobrevida a 5 y 10 años (58%-55,2% vs. 67%-63%; p<0,001). Según la OME, los CCRP se presentaron en 61,3% por lesiones omitidas en colonoscopias inadecuadas, 29% colonoscopias adecuadas y 9,7% resecciones incompletas de adenomas. En conclusión, la tasa de CCRP fue de 6,9%, con mayor propensión en pacientes de mayores, antecedente de resección de pólipos, y en colon derecho. Acorde a la OME, las lesiones omitidas más frecuentemente se relacionaron con colonoscopias inadecuadas. Los pacientes con CCRP tienen menor sobrevida.","PeriodicalId":35807,"journal":{"name":"Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135039730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Massive pulmonary thromboembolism in a patient with Crohn's disease and latent tuberculosis treated with ustekinumab]. [使用ustekinumab治疗的克罗恩病和潜伏性肺结核患者出现大量肺血栓栓塞]。
Siomara Aransuzú Chávez-Sánchez, Hugo Cedrón-Cheng

Inflammatory bowel disease (IBD) is a spectrum of chronic immune-mediated diseases that affect the gastrointestinal tract and other extraintestinal systems, behaving as a systemic disease. Thromboembolic phenomena are a frequent complication in IBD, because of hypercoagulability states associated with disease activity, and their presence has a negative impact on prognosis and patient survival. Due to this, the control of the inflammatory activity of IBD is one of the pillars in the control of thromboembolic events. Biological drugs are associated with rapid control of the inflammatory process, however, the security profile for the reactivation of latent infections, particularly tuberculosis, is always discussed. We present the case of a 37-year-old patient who presented with deep vein thrombosis in the left lower limb and later with massive pulmonary thromboembolism. During his evaluation, he was diagnosed with Crohn's disease (CD). When carrying out the studies prior to the use of biologics, PPD and quantiferon tests were positive. After discussing the case, we decided to start treatment with ustekinumab.

炎症性肠病(IBD)是一系列影响胃肠道和其他肠外系统的慢性免疫介导疾病,表现为系统性疾病。血栓栓塞现象是IBD的常见并发症,因为高凝状态与疾病活动有关,其存在对预后和患者生存有负面影响。因此,控制IBD的炎症活性是控制血栓栓塞事件的支柱之一。生物药物与炎症过程的快速控制有关,然而,潜伏感染,特别是结核病的再激活的安全性一直在讨论中。我们报告了一例37岁的患者,他出现左下肢深静脉血栓形成,后来出现大量肺血栓栓塞。在评估期间,他被诊断为克罗恩病(CD)。在使用生物制剂之前进行研究时,PPD和quantiferon测试呈阳性。在讨论了这个病例后,我们决定开始使用ustekinumab进行治疗。
{"title":"[Massive pulmonary thromboembolism in a patient with Crohn's disease and latent tuberculosis treated with ustekinumab].","authors":"Siomara Aransuzú Chávez-Sánchez,&nbsp;Hugo Cedrón-Cheng","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD) is a spectrum of chronic immune-mediated diseases that affect the gastrointestinal tract and other extraintestinal systems, behaving as a systemic disease. Thromboembolic phenomena are a frequent complication in IBD, because of hypercoagulability states associated with disease activity, and their presence has a negative impact on prognosis and patient survival. Due to this, the control of the inflammatory activity of IBD is one of the pillars in the control of thromboembolic events. Biological drugs are associated with rapid control of the inflammatory process, however, the security profile for the reactivation of latent infections, particularly tuberculosis, is always discussed. We present the case of a 37-year-old patient who presented with deep vein thrombosis in the left lower limb and later with massive pulmonary thromboembolism. During his evaluation, he was diagnosed with Crohn's disease (CD). When carrying out the studies prior to the use of biologics, PPD and quantiferon tests were positive. After discussing the case, we decided to start treatment with ustekinumab.</p>","PeriodicalId":35807,"journal":{"name":"Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61565574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Start of enteral nutrition after an endoscopic gastrostomy, is it necessary to wait?] [内镜胃造口术后开始肠内营养,是否需要等待?]
William Otero-Regino, Hernando Marulanda-Fernández, Gilberto Jaramillo-Trujillo, Lina Otero-Parra, Julián Parga-Bermúdez, Felipe Vera-Polanía, Juan Antonio Trejos-Naranjo, Elder Otero Ramos

Traditionally, the initiation of enteral nutrition after a percutaneous endoscopic gastrostomy (PEG) is performed between 12 and 24 hours. Different research suggests that early initiation might be a safe option. Our aim was to determine whether starting enteral nutrition 4 hours after performing PEG is a safe practice in terms of risk of intolerance, complications, or death, compared to starting it at 12 hours. We carried out a prospective, randomized, multicenter study in third and fourth level institutions in Bogotá and Cundinamarca, between June 2020 and May 2022, 117 patients were included who were randomized into 2 groups, group A with early nutrition initiation (4 hours), and standard group B (12 hours). The most frequent mechanism of dysphagia was cerebrovascular disease (43%), followed by complications of COVID19 infection (26%). There were no statistically significant differences between the groups evaluated regarding the percentage of intolerance to nutrition, RR = 0.93 (CI 0.30-2.90), there were also no differences in terms of postoperative complications, (RR) = 0.34 (CI 0.09-1.16), and no differences were found in mortality between the evaluated groups, (RR) = 1.12 (CI 0.59-2.15). In conclusion, early initiation of nutrition through the gastrostomy, 4 hours after performing the PEG, is a safe behavior that is not related to greater intolerance to nutrition, complications, or death, compared to later initiation.

传统上,经皮内镜胃造瘘术(PEG)后的肠内营养开始时间为12至24小时。不同的研究表明,早期启动可能是一个安全的选择。我们的目的是确定在进行PEG后4小时开始肠内营养与在12小时开始肠外营养相比,在不耐受、并发症或死亡风险方面是否是一种安全的做法。2020年6月至2022年5月,我们在波哥大和昆迪纳马卡的三级和四级机构进行了一项前瞻性、随机、多中心研究,纳入117名患者,他们被随机分为两组,a组早期营养启动(4小时)和标准B组(12小时)。吞咽困难最常见的机制是脑血管疾病(43%),其次是COVID19感染的并发症(26%)。评估组之间对营养不耐受的百分比没有统计学上的显著差异,RR=0.93(CI 0.30-2.90),术后并发症也没有差异,(RR)=0.34(CI 0.09-1.16),评估组之间的死亡率也没有差异(RR)=1.12(CI 0.59-2.15)。总之,在进行PEG后4小时,通过胃造口术早期开始营养是一种安全的行为,与后期开始相比,这与更大的营养不耐受、并发症或死亡无关。
{"title":"[Start of enteral nutrition after an endoscopic gastrostomy, is it necessary to wait?]","authors":"William Otero-Regino,&nbsp;Hernando Marulanda-Fernández,&nbsp;Gilberto Jaramillo-Trujillo,&nbsp;Lina Otero-Parra,&nbsp;Julián Parga-Bermúdez,&nbsp;Felipe Vera-Polanía,&nbsp;Juan Antonio Trejos-Naranjo,&nbsp;Elder Otero Ramos","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Traditionally, the initiation of enteral nutrition after a percutaneous endoscopic gastrostomy (PEG) is performed between 12 and 24 hours. Different research suggests that early initiation might be a safe option. Our aim was to determine whether starting enteral nutrition 4 hours after performing PEG is a safe practice in terms of risk of intolerance, complications, or death, compared to starting it at 12 hours. We carried out a prospective, randomized, multicenter study in third and fourth level institutions in Bogotá and Cundinamarca, between June 2020 and May 2022, 117 patients were included who were randomized into 2 groups, group A with early nutrition initiation (4 hours), and standard group B (12 hours). The most frequent mechanism of dysphagia was cerebrovascular disease (43%), followed by complications of COVID19 infection (26%). There were no statistically significant differences between the groups evaluated regarding the percentage of intolerance to nutrition, RR = 0.93 (CI 0.30-2.90), there were also no differences in terms of postoperative complications, (RR) = 0.34 (CI 0.09-1.16), and no differences were found in mortality between the evaluated groups, (RR) = 1.12 (CI 0.59-2.15). In conclusion, early initiation of nutrition through the gastrostomy, 4 hours after performing the PEG, is a safe behavior that is not related to greater intolerance to nutrition, complications, or death, compared to later initiation.</p>","PeriodicalId":35807,"journal":{"name":"Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61565576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Endoscopic retrieval of migrated gastric band]. [胃束带移位的内窥镜检索]。
Juan Antonio Chirinos-Vega, Eduardo Vesco-Monteagudo, Patricia Valera-Luján, Aurelio Barboza-Beraún

This is a case report of a 47-year-old woman, carrier of an adjustable gastric band since 2018, that developed abdominal pain due to partial migration into the stomach. which was successfully removed endoscopically using Sohendra's lithotriptor.

这是一例47岁女性的病例报告,她自2018年以来一直携带可调节胃束带,由于部分迁移到胃中而出现腹痛。使用Sohendra的碎石机在内镜下成功取出。
{"title":"[Endoscopic retrieval of migrated gastric band].","authors":"Juan Antonio Chirinos-Vega, Eduardo Vesco-Monteagudo, Patricia Valera-Luján, Aurelio Barboza-Beraún","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This is a case report of a 47-year-old woman, carrier of an adjustable gastric band since 2018, that developed abdominal pain due to partial migration into the stomach. which was successfully removed endoscopically using Sohendra's lithotriptor.</p>","PeriodicalId":35807,"journal":{"name":"Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61565571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Generation of a predictive test for the diagnosis of the etiology of variceal upper gastrointestinal bleeding]. [用于诊断静脉曲张性上消化道出血病因的预测性测试的产生]。
Luis Yasser Pérez-Condori, Arnold Esthif Alvarado-Malca, César Antonio Loza-Munarriz, Jorge Luis Espinoza-Ríos

Our objective was to develop a diagnostic test to predict the etiology of Variceal Upper Gastrointestinal Bleeding (VUGIB). We conducted a retrospective cohort study. Medical records of patients over 18 years of age with Upper Gastrointestinal Bleeding (UGIB) who attended the emergency service of Hospital Cayetano Heredia (HCH) in Lima-Peru between 2019 and 2022 were reviewed; demographic, laboratory and clinical data were collected. Subsequently, predictive variables of variceal upper gastrointestinal bleeding (VUGIB) were identified using multiple logistic regression. Each variable with predictive capacity was assigned a score with a cut-off point and served to build a predictive scale for VUGIB. 197 medical records of patients with UGIB were included, of which 127 (64%) had non-variceal bleeding, and 70 (36%), variceal. Four independent predictors were identified: hematemesis (red vomit) (OR: 4,192, 95% CI: 1.586-11.082), platelet count (OR: 3.786, 95% CI: 1.324-10.826), history of UGIB (OR: 2.634, 95% CI: 1.017-6.820), signs of chronic liver disease (OR: 11.244, 95% CI: 3.067-35.047), with which a predictive scale was constructed, with a cut-off point >7 and ≤7; which showed a sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, and negative of 58.6%, 90.6%, 77.4%, 79.9%, 6.20, and 0.46 respectively. In conclusion, the predictive scale with a cut-off point >7 is useful for predicting the presence of VUGIB in patients who attend the emergency room for UGIB.

我们的目的是开发一种诊断测试来预测静脉曲张性上消化道出血(VUGIB)的病因。我们进行了一项回顾性队列研究。回顾了2019年至2022年间在秘鲁利马Cayetano Heredia医院(HCH)急诊服务的18岁以上上消化道出血(UGIB)患者的医疗记录;收集人口统计学、实验室和临床数据。随后,使用多元逻辑回归确定静脉曲张性上消化道出血(VUGIB)的预测变量。每个具有预测能力的变量都被分配了一个带有截止点的分数,并用于建立VUGIB的预测量表。包括197例UGIB患者的医疗记录,其中127例(64%)为非静脉曲张出血,70例(36%)为静脉曲张出血。确定了四个独立的预测因素:吐血(红色呕吐物)(OR:4192,95%CI:1.586-11.082)、血小板计数(OR:3.786,95%CI:1.324-10.826)、UGIB病史(OR:2.634,95%CI:1.017-6.820)、慢性肝病体征(OR:12.444,95%CI:3.067-35.047),据此构建预测量表,分界点>7且≤7;其敏感性、特异性、阳性预测值、阴性预测值、阳性似然比和阴性分别为58.6%、90.6%、77.4%、79.9%、6.20和0.46。总之,临界点>7的预测量表有助于预测因UGIB进入急诊室的患者是否存在VUGIB。
{"title":"[Generation of a predictive test for the diagnosis of the etiology of variceal upper gastrointestinal bleeding].","authors":"Luis Yasser Pérez-Condori,&nbsp;Arnold Esthif Alvarado-Malca,&nbsp;César Antonio Loza-Munarriz,&nbsp;Jorge Luis Espinoza-Ríos","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Our objective was to develop a diagnostic test to predict the etiology of Variceal Upper Gastrointestinal Bleeding (VUGIB). We conducted a retrospective cohort study. Medical records of patients over 18 years of age with Upper Gastrointestinal Bleeding (UGIB) who attended the emergency service of Hospital Cayetano Heredia (HCH) in Lima-Peru between 2019 and 2022 were reviewed; demographic, laboratory and clinical data were collected. Subsequently, predictive variables of variceal upper gastrointestinal bleeding (VUGIB) were identified using multiple logistic regression. Each variable with predictive capacity was assigned a score with a cut-off point and served to build a predictive scale for VUGIB. 197 medical records of patients with UGIB were included, of which 127 (64%) had non-variceal bleeding, and 70 (36%), variceal. Four independent predictors were identified: hematemesis (red vomit) (OR: 4,192, 95% CI: 1.586-11.082), platelet count (OR: 3.786, 95% CI: 1.324-10.826), history of UGIB (OR: 2.634, 95% CI: 1.017-6.820), signs of chronic liver disease (OR: 11.244, 95% CI: 3.067-35.047), with which a predictive scale was constructed, with a cut-off point >7 and ≤7; which showed a sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, and negative of 58.6%, 90.6%, 77.4%, 79.9%, 6.20, and 0.46 respectively. In conclusion, the predictive scale with a cut-off point >7 is useful for predicting the presence of VUGIB in patients who attend the emergency room for UGIB.</p>","PeriodicalId":35807,"journal":{"name":"Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61565572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[To cure sometimes, to relieve often, to comfort always]. [有时治愈,经常缓解,总是安慰]。
Hugo Guillermo Cedrón-Cheng
{"title":"[To cure sometimes, to relieve often, to comfort always].","authors":"Hugo Guillermo Cedrón-Cheng","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":35807,"journal":{"name":"Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61565577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Post-colonoscopy colorectal cancer: Evaluation of a cohort in its clinical and colonoscopic characteristics, survival and its causes according to the World Endoscopy Organization]. [结肠镜检查后癌症:根据世界内窥镜组织对其临床和结肠镜特征、生存率及其原因的队列评估]。
Rodrigo Castaño-Llano, Diego Caycedo-Medina, Juan Darío Puerta, Juan Ricardo Jaramillo, Luis Palacios, Mauricio Rodríguez, Sandra Molina, Camilo Vásquez, Santiago Salazar, Juan Esteban Puerta, Isabella Cadavid

Post-colonoscopy colorectal cancer (PCCRC) is a tumor that appears after a normal colonoscopy before the established time for the endoscopic follow up. Its origin reflects the quality of the colonoscopy and the different tumoral biologics between the CRC and the CRCPC. Our aim is to describe the characteristics of the PCCRC in our region, to identify risk factors, to discriminate the potential causes according to the World Endoscopý Organization (WEO) and to determine its impact in the patient's survival. We studied patients with colorectal cancer (CRC) attended at the gastro-oncology clinic of two institutions of Medellin-Colombia, between January 2012 and December 2021 that had been submitted to a colonoscopy between 6-36 months before the colonoscopy in which the CRC was diagnosed. 919 patients during 10 years for CRC, 68 cases of PCCRC (6.9%); It was more frequent in older patients (74 vs. 66 years; p=0.03), with background of adenomatous polyps (36.8% vs. 20.1%; p=0.01) and in right colon (57.4% vs. 40.6%; p=0.006), with a tendency in patients with diverticulosis (41.2% vs. 31.3%; p=0.05) and diabetes (25% vs. 14%; p=0.06); less survival at 5 and 10 years (58% and 55.2% vs. 67% and 63%; p < 0.001). According to the WEO, the PCCRC presents in 61.3% because of abnormal findings omitted in inadequate colonoscopies, 29% in a suitable colonoscopy and 9.7% incomplete resections of adenomas. In conclusion, the rate of PCCRC was 6.9% with more propension in older patients, a background of polyp resection, and proximal colon. According to the WEO, the abnormal findings omitted more frequently were related with inadequate colonoscopies. The patients with PCCRC had less survival.

结肠镜检查后癌症(PCCRC)是一种在正常结肠镜检查之后,在确定的内窥镜随访时间之前出现的肿瘤。它的起源反映了结肠镜检查的质量以及CRC和CRCPC之间不同的肿瘤生物制品。我们的目的是描述我们地区PCCRC的特征,确定风险因素,根据世界内窥镜组织(WEO)区分潜在原因,并确定其对患者生存的影响。我们研究了2012年1月至2021年12月期间在麦德林-哥伦比亚两个机构的肠胃科诊所就诊的癌症(CRC)患者,这些患者在诊断为CRC的结肠镜检查前6-36个月接受了结肠镜检查。919例CRC患者,68例PCCRC(6.9%);更常见于老年患者(74岁对66岁;p=0.03)、腺瘤性息肉背景患者(36.8%对20.1%;p=0.01)和右结肠患者(57.4%对40.6%;p=0.006),有憩室病(41.2%对31.3%;p=0.05)和糖尿病患者(25%对14%;p=0.06)的趋势;5年和10年的生存率较低(58%和55.2%对67%和63%;p<0.001)。根据WEO,PCCRC的出现率为61.3%,原因是结肠镜检查不充分时遗漏了异常发现,29%是在合适的结肠镜检查中,9.7%是腺瘤切除不全。总之,PCCRC的发生率为6.9%,在老年患者、息肉切除背景和近端结肠中有更大的发展。根据WEO的说法,更频繁遗漏的异常发现与结肠镜检查不充分有关。PCCRC患者的生存率较低。
{"title":"[Post-colonoscopy colorectal cancer: Evaluation of a cohort in its clinical and colonoscopic characteristics, survival and its causes according to the World Endoscopy Organization].","authors":"Rodrigo Castaño-Llano,&nbsp;Diego Caycedo-Medina,&nbsp;Juan Darío Puerta,&nbsp;Juan Ricardo Jaramillo,&nbsp;Luis Palacios,&nbsp;Mauricio Rodríguez,&nbsp;Sandra Molina,&nbsp;Camilo Vásquez,&nbsp;Santiago Salazar,&nbsp;Juan Esteban Puerta,&nbsp;Isabella Cadavid","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Post-colonoscopy colorectal cancer (PCCRC) is a tumor that appears after a normal colonoscopy before the established time for the endoscopic follow up. Its origin reflects the quality of the colonoscopy and the different tumoral biologics between the CRC and the CRCPC. Our aim is to describe the characteristics of the PCCRC in our region, to identify risk factors, to discriminate the potential causes according to the World Endoscopý Organization (WEO) and to determine its impact in the patient's survival. We studied patients with colorectal cancer (CRC) attended at the gastro-oncology clinic of two institutions of Medellin-Colombia, between January 2012 and December 2021 that had been submitted to a colonoscopy between 6-36 months before the colonoscopy in which the CRC was diagnosed. 919 patients during 10 years for CRC, 68 cases of PCCRC (6.9%); It was more frequent in older patients (74 vs. 66 years; p=0.03), with background of adenomatous polyps (36.8% vs. 20.1%; p=0.01) and in right colon (57.4% vs. 40.6%; p=0.006), with a tendency in patients with diverticulosis (41.2% vs. 31.3%; p=0.05) and diabetes (25% vs. 14%; p=0.06); less survival at 5 and 10 years (58% and 55.2% vs. 67% and 63%; p < 0.001). According to the WEO, the PCCRC presents in 61.3% because of abnormal findings omitted in inadequate colonoscopies, 29% in a suitable colonoscopy and 9.7% incomplete resections of adenomas. In conclusion, the rate of PCCRC was 6.9% with more propension in older patients, a background of polyp resection, and proximal colon. According to the WEO, the abnormal findings omitted more frequently were related with inadequate colonoscopies. The patients with PCCRC had less survival.</p>","PeriodicalId":35807,"journal":{"name":"Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61565575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vanek's tumor: a rare differential diagnosis of colonic submucosal lesions. Vanek肿瘤:结肠黏膜下病变的罕见鉴别诊断。
Diego Berrospi-Castillo, Elsy Sotomayor-Trelles, Harold Benites Goñi

Gastrointestinal submucosal lesions represent a diagnostic challenge, including benign or malignant lesions, so they are identified more accurately by histopathological study accompanied by immunohistochemistry. This is a case of a 21-year-old man with a bleeding submucosal lesion in the cecum. The patient underwent a right colectomy. Microscopic finding was compatible with Vanek's tumor.

胃肠道黏膜下病变是一个诊断挑战,包括良性或恶性病变,因此通过组织病理学研究和免疫组织化学可以更准确地识别它们。这是一例21岁男性盲肠粘膜下病变出血的病例。病人接受了右半结肠切除术。显微镜检查结果与Vanek的肿瘤相符。
{"title":"Vanek's tumor: a rare differential diagnosis of colonic submucosal lesions.","authors":"Diego Berrospi-Castillo,&nbsp;Elsy Sotomayor-Trelles,&nbsp;Harold Benites Goñi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Gastrointestinal submucosal lesions represent a diagnostic challenge, including benign or malignant lesions, so they are identified more accurately by histopathological study accompanied by immunohistochemistry. This is a case of a 21-year-old man with a bleeding submucosal lesion in the cecum. The patient underwent a right colectomy. Microscopic finding was compatible with Vanek's tumor.</p>","PeriodicalId":35807,"journal":{"name":"Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61565581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Hepatotoxicity by tamsulosin / dutasteride: report of a probable case]. [坦索罗辛/度他司胺肝毒性:一例可能病例的报告]。
Stalin Yance, Pedro Montes

Tamsulosin and dutasteride are drugs widely used to treat benign prostatic hypertrophy. having a good safety profile. There are few reports of liver injury associated with the use of tamsulosin; however, there are no reports of hepatic toxicity from the use of dutasteride and the combined use of tamsulosin/dutasteride. We present the case of a 64-year-old man who developed liver injury after the combined use of tamsulosin/dutasteride, developing a pattern of hepatocellular damage and acute hepatitis symptoms. Viral, autoimmune, and metabolic storage diseases of the liver were ruled out, as well as biliary pathology by means of abdominal ultrasound and resonance cholangiography. In the causality evaluation, CIOMS-RUCAM presented: 6 points (probable) and Naranjo: 4 points (possible). The patient presented a clinical and laboratory response after discontinuing the drug.

Tamsulosin和dutasteride是广泛用于治疗良性前列腺肥大的药物。具有良好的安全性。很少有与使用坦索罗辛相关的肝损伤报告;然而,目前还没有使用杜他司胺和坦洛新/杜他司肽联合使用的肝毒性报告。我们报告了一例64岁的男性患者,他在联合使用坦索罗辛/度他司胺后出现肝损伤,出现肝细胞损伤和急性肝炎症状。通过腹部超声和共振胆管造影,排除了肝脏的病毒性、自身免疫性和代谢性储存疾病,以及胆道病理。在因果关系评估中,CIOMS-RUCAM表示:6分(可能),Naranjo表示:4分(可能的)。患者停药后出现临床和实验室反应。
{"title":"[Hepatotoxicity by tamsulosin / dutasteride: report of a probable case].","authors":"Stalin Yance,&nbsp;Pedro Montes","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tamsulosin and dutasteride are drugs widely used to treat benign prostatic hypertrophy. having a good safety profile. There are few reports of liver injury associated with the use of tamsulosin; however, there are no reports of hepatic toxicity from the use of dutasteride and the combined use of tamsulosin/dutasteride. We present the case of a 64-year-old man who developed liver injury after the combined use of tamsulosin/dutasteride, developing a pattern of hepatocellular damage and acute hepatitis symptoms. Viral, autoimmune, and metabolic storage diseases of the liver were ruled out, as well as biliary pathology by means of abdominal ultrasound and resonance cholangiography. In the causality evaluation, CIOMS-RUCAM presented: 6 points (probable) and Naranjo: 4 points (possible). The patient presented a clinical and laboratory response after discontinuing the drug.</p>","PeriodicalId":35807,"journal":{"name":"Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61565573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nasogastric versus nasojejunal tube feeding for severe acute pancreatitis: A systematic review of randomized controlled trials. 鼻胃与鼻空肠管饲治疗重症急性胰腺炎:随机对照试验的系统综述。
Andrea Carlin-Ronquillo, Harold Benites-Goñi, Carlos Diaz-Arocutipa, Paulo Alosilla Sandoval, Alejandro Piscoya-Rivera, Lesly Calixto, Adrian V Hernández

Early enteral nutrition through a feeding tube is essential for the management of severe acute pancreatitis (SAP). Nasojejunal tube nutrition has been preferred on the assumption that it provided pancreatic rest in comparison to the nasogastric tube. However, nasojejunal tube placement is complex, may delay feeding initiation and can increase hospital costs. Our aim was to compare the efficacy and safety of enteral feeding with a nasogastric tube versus nasojejunal tube in patients with SAP. We searched four databases (PubMed, Web of Science, Scopus, and Embase) until December 1, 2022. We included randomized controlled trials (RCTs) comparing enteral feeding by nasogastric and nasojejunal tubes in patients with SAP. Primary outcome was all-cause mortality. Secondary outcomes were organ failure, infection, complications, surgical intervention, duration of tube feeding and length of hospital stay. Risk of bias assessment was completed independently by two investigators using the Cochrane RoB 2.0 tool. We performed random effects model meta-analyses using the inverse variance method. Effect measures were reported as relative risks (RR) and their 95% CIs for dichotomous outcomes and mean differences (MD) and their 95% CIs for continuous outcomes. We included four RCTs involving 192 patients with SAP. The mean ages ranged between 36 and 62 years old. There was no significant difference in all-cause mortality between the nasogastric and nasojejunal feeding arms (18/98 vs. 23/93; RR 1.34, 95%CI 0.77-2.30; p=0.30). There were no significant differences in all secondary outcomes between feeding arms. There were three RCTs with some concerns of bias, in the randomization process. In conclusion, in patients with SAP, enteral feeding delivered by nasogastric tube was as efficacious and safe as nasojejunal tube. Further randomized controlled trials with more participants and better design are needed to confirm these findings.

通过饲管进行早期肠内营养对重症急性胰腺炎(SAP)的治疗至关重要。Nasojejunal管营养是首选的,因为与鼻胃管相比,它可以提供胰腺休息。然而,鼻空肠导管的放置是复杂的,可能会延迟进食开始,并可能增加医院费用。我们的目的是比较SAP患者使用鼻胃导管和鼻空肠导管进行肠内喂养的疗效和安全性。我们搜索了四个数据库(PubMed、Web of Science、Scopus和Embase),直到2022年12月1日。我们纳入了随机对照试验(RCT),比较了SAP患者通过鼻胃管和鼻空肠管进行的肠内喂养。主要结果是全因死亡率。次要结果是器官衰竭、感染、并发症、手术干预、管饲持续时间和住院时间。两名研究人员使用Cochrane RoB 2.0工具独立完成了偏倚风险评估。我们使用逆方差方法进行了随机效应模型荟萃分析。效果测量报告为相对风险(RR)及其95%CI(用于二分结果)和平均差异(MD)及其95%置信区间(用于连续结果)。我们纳入了四项随机对照试验,涉及192名SAP患者。平均年龄在36至62岁之间。鼻胃和鼻空肠喂养组的全因死亡率没有显著差异(18/98 vs.23/93;RR 1.34,95%CI 0.77-2.30;p=0.30)。喂养组之间的所有次要结果没有显著差异。在随机化过程中,有三项随机对照试验存在一些偏倚问题。总之,在SAP患者中,鼻胃导管肠内喂养与鼻空肠导管一样有效和安全。需要有更多参与者和更好设计的进一步随机对照试验来证实这些发现。
{"title":"Nasogastric versus nasojejunal tube feeding for severe acute pancreatitis: A systematic review of randomized controlled trials.","authors":"Andrea Carlin-Ronquillo,&nbsp;Harold Benites-Goñi,&nbsp;Carlos Diaz-Arocutipa,&nbsp;Paulo Alosilla Sandoval,&nbsp;Alejandro Piscoya-Rivera,&nbsp;Lesly Calixto,&nbsp;Adrian V Hernández","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Early enteral nutrition through a feeding tube is essential for the management of severe acute pancreatitis (SAP). Nasojejunal tube nutrition has been preferred on the assumption that it provided pancreatic rest in comparison to the nasogastric tube. However, nasojejunal tube placement is complex, may delay feeding initiation and can increase hospital costs. Our aim was to compare the efficacy and safety of enteral feeding with a nasogastric tube versus nasojejunal tube in patients with SAP. We searched four databases (PubMed, Web of Science, Scopus, and Embase) until December 1, 2022. We included randomized controlled trials (RCTs) comparing enteral feeding by nasogastric and nasojejunal tubes in patients with SAP. Primary outcome was all-cause mortality. Secondary outcomes were organ failure, infection, complications, surgical intervention, duration of tube feeding and length of hospital stay. Risk of bias assessment was completed independently by two investigators using the Cochrane RoB 2.0 tool. We performed random effects model meta-analyses using the inverse variance method. Effect measures were reported as relative risks (RR) and their 95% CIs for dichotomous outcomes and mean differences (MD) and their 95% CIs for continuous outcomes. We included four RCTs involving 192 patients with SAP. The mean ages ranged between 36 and 62 years old. There was no significant difference in all-cause mortality between the nasogastric and nasojejunal feeding arms (18/98 vs. 23/93; RR 1.34, 95%CI 0.77-2.30; p=0.30). There were no significant differences in all secondary outcomes between feeding arms. There were three RCTs with some concerns of bias, in the randomization process. In conclusion, in patients with SAP, enteral feeding delivered by nasogastric tube was as efficacious and safe as nasojejunal tube. Further randomized controlled trials with more participants and better design are needed to confirm these findings.</p>","PeriodicalId":35807,"journal":{"name":"Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61565580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1